At mBIOTA Labs, we create clinically proven medical foods for patients with GI disorders - combining scientific rigor with empathy and respect for the patient experience. Read published research featuring mBIOTA's elemental diet formula.
Published Research
Clinical Evidence
At mBIOTA Labs, we create clinically proven medical foods for patients with GI disorders - combining scientific rigor with empathy and respect for the patient experience. Read published research featuring mBIOTA's elemental diet formula.
As published in Clinical Gastroenterology and Hepatology
2023 Prospective Clinical Study
Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients with Intestinal Microbial Overgrowth
Our 2023 clinical trial of a 2 week course of mBIOTA in SIBO and IMO patients. The mBIOTA Elemental diet was tolerated by 100% of patients, eradicated overgrowth in 73% of patients overall and provided adequate relief from symptoms in 83% of patients.
As published in Clinical Gastroenterology and Hepatology
2023 Prospective Clinical Study
Effect, Tolerability, and Safety of Exclusive Palatable Elemental Diet in Patients with Intestinal Microbial Overgrowth
Our 2023 clinical trial of a 2 week course of mBIOTA in SIBO and IMO patients. The mBIOTA Elemental diet was tolerated by 100% of patients, eradicated overgrowth in 73% of patients overall and provided adequate relief from symptoms in 83% of patients.
Successful Outpatient Management of Partial Small Bowel Obstruction
A 2 week outpatient course of mBIOTA Elemental Diet successfully resolved symptoms and improved bowel dilation in a patient with a partial small bowel obstruction.
Reduction of Methane Levels Correlates with Fecal Abundance of M. smithii
An exclusive 2-week course of mBIOTA demonstrated a prolonged reduction in M. smithii levels for at least two weeks post-completion, which was associated with a corresponding decrease in breath methane levels in individuals with IMO.
Maintained Visceral and Total Body Fat Loss Following Elemental Diet
A 2 week exclusive course of mBIOTA leads to a significant reduction in body fat percentage and visceral fat area with a minimal drop in lean weight.
Achieving Organoleptic Acceptability with Elemental Formula
In this prospective, single-blind comparative study, mBIOTA was significantly more palatable than a conventional elemental diet and resulted in optimal patient compliance during a 2-week exclusive elemental diet therapy.
Compliance, Safety, and Effect of Exclusive Palatable Elemental Diet in Microbial Overgrowth
A 2-week mBIOTA elemental diet normalized breath tests in 73% of IMO/SIBO patients. The diet demonstrated a favorable safety profile and achieved the highest known compliance rate for an oral elemental diet.
Successful Outpatient Management of Partial Small Bowel Obstruction
A 2 week outpatient course of mBIOTA Elemental Diet successfully resolved symptoms and improved bowel dilation in a patient with a partial small bowel obstruction.
Reduction of Methane Levels Correlates with Fecal Abundance of M. smithii
An exclusive 2-week course of mBIOTA demonstrated a prolonged reduction in M. smithii levels for at least two weeks post-completion, which was associated with a corresponding decrease in breath methane levels in individuals with IMO.
Maintained Visceral and Total Body Fat Loss Following Elemental Diet
A 2 week exclusive course of mBIOTA leads to a significant reduction in body fat percentage and visceral fat area with a minimal drop in lean weight.
Achieving Organoleptic Acceptability with Elemental Formula
In this prospective, single-blind comparative study, mBIOTA was significantly more palatable than a conventional elemental diet and resulted in optimal patient compliance during a 2-week exclusive elemental diet therapy.
Compliance, Safety, and Effect of Exclusive Palatable Elemental Diet in Microbial Overgrowth
A 2-week mBIOTA elemental diet normalized breath tests in 73% of IMO/SIBO patients. The diet demonstrated a favorable safety profile and achieved the highest known compliance rate for an oral elemental diet.
Medical Advisors
Our Medical Advisors are internationally recognized leaders in gastroenterology and microbiome research. This multidisciplinary panel plays a critical role in shaping our clinical and scientific strategy, ensuring that our innovations are guided by rigorous evidence, ethical standards, and the highest level of medical insight. Meet some of the specialists helping us bridge academic research and real-world application.
Dr. Mark Pimentel, MD
Mark Pimentel, MD, FRCP(C) is a gastroenterology physician-scientist in Los Angeles, as well as a professor of medicine and gastroenterology. A pioneering expert in irritable bowel syndrome (IBS), Dr. Pimentel has spent decades advancing the research and understanding of Small Intestinal Bacterial Overgrowth (SIBO) and its role therein.
Dr. Pimentel's decades of gastroenterological research led him to develop the Low Fermentation Eating (LFE) diet to help SIBO sufferers enjoy a less restrictive diet and lifestyle.
Dr. Pimentel’s work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others.
Pimentel has served as a principal investigator or co-investigator for numerous translational and clinical investigations of IBS and the relationship between gut flora composition and human disease. Dr. Pimentel is a diplomate of the American Board of Internal Medicine, a fellow of the Royal College of Physicians and Surgeons of Canada, and a member of the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.
Dr. Ali Rezaie, MD, MSc
Ali Rezaie, MD, MSc, FRCP(C) is a gastroenterology physician-scientist in Los Angeles where he specializes in microbiome research and gastrointestinal motility disorders.
Beyond his background in internal medicine and gastroenterology, he has also specialized inflammatory bowel diseases (IBD) as well as epidemiology. To date, Dr. Rezaie has published more than 150 peer-reviewed papers that have been cited over 10,000 times.
Rezaie has been awarded multiple grants from prestigious organizations including the Canadian Institutes of Health Research fellowship, the American College of Gastroenterology Research and the Kenneth Rainin Foundation. He also serves as the associate editor of Digestive Diseases and Sciences, a peer-reviewed journal of gastroenterology and hepatology. His research focuses on microbiome, irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), medical device development, and internal UV therapy.
William Chey, MD
Professor of Gastroenterology & Nutritional Sciences, IBS Expert
- 2026 American College of Gastroenterology (ACG) President
- Rome Foundation Board of Directors
- IFFGD Board of Directors
- Distinguished Clinician Award American Gastroentological Association
Nick Talley, MD/PhD
World Renowned Neurogastroenterologist and Physician Scientist, Distinguished Laureate Professor
- Emeritus Editor in Chief of the Medical Journal of Australia
- Former President of the Royal Australian College of Physicians
- Rome Foundation Lifetime Achievement Award
Walter Park, MD
Associate Professor of Gastroenterology & Hepatology, Pancreatic Disorders Expert
- Leading authority in the field of pancreatic research
- Principal Investigator within an NIDDK/NCI Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreas Cancer (CPDPC)
- Clinician Scientist
Ruchi Mathur, MD
Endocrinologist, Microbiome and Metabolic Disease Expert
- Fellow of the Royal College of Physicians of Canada (FRCPC)
- Leading Authority on the effects of gastrointestinal microbiota on metabolic diseases
William Chey, MD
Professor of Gastroenterology & Nutritional Sciences, IBS Expert
- 2026 American College of Gastroenterology (ACG) President
- Rome Foundation Board of Directors
- IFFGD Board of Directors
- Distinguished Clinician Award American Gastroentological Association
Walter Park, MD
Associate Professor of Gastroenterology & Hepatology, Pancreatic Disorders Expert
- Leading authority in the field of pancreatic research
- Principal Investigator within an NIDDK/NCI Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreas Cancer (CPDPC)
- Clinician Scientist
Nick Talley, MD/PhD
World Renowned Neurogastroenterologist and Physician Scientist, Distinguished Laureate Professor
- Emeritus Editor in Chief of the Medical Journal of Australia
- President of the Royal Australian College of Physicians (2014-2016)
- Rome Foundation Lifetime Achievement Award (2011)
Ruchi Mathur, MD
Endocrinologist, Microbiome and Metabolic Disease Expert
- Fellow of the Royal College of Physicians of Canada (FRCPC)
- Leading Authority on the effects of gastrointestinal microbiota on metabolic diseases
Richard Weinberg, MD
Professor of Internal Medicine and Integrative Physiology & Pharmacology
- Leading Authority on Taste Perception
- Expert in IBS and nutritional disorders
- Clinician Scientist
Meena Bansal, MD
Professor of Medicine, Liver Disease Expert
- Fellow of the American Association for the Study of Liver Diseases (FAASLD)
- Clinician Scientist
Maitreyi Kohandaraman, MD
Associate Professor of Medicine, Gastroenterologist and Physician Nutrition Specialist, IBD Expert
- Fellow of the Royal College of Physicians of Canada (FRCPC)
- Director of LyfeMD, leading authority on the interplay of nutrition and the gut microbiome
- Clinician Scientist
Richard Weinberg, MD
Professor of Internal Medicine and Integrative Physiology & Pharmacology
- Leading Authority on Taste Perception
- Expert in IBS and nutritional disorders
- Clinician Scientist
Maitreyi Kohandaraman, MD
Associate Professor of Medicine, Gastroenterologist and Physician Nutrition Specialist, IBD Expert
- Fellow of the Royal College of Physicians of Canada (FRCPC)
- Director of LyfeMD, leading authority on the interplay of nutrition and the gut microbiome
- Clinician Scientist
Meena Bansal, MD
Professor of Medicine, Liver Disease Expert
- Former Secretary for the American Association for the Study of Liver
- Clinician Scientist